Drug and Medication Analysis & Statistics, October 2014 (p5)

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publishers

All regions

You might be interested in: Drug, Vaccine, Smoking Cessation, more »

121-170 of about 4 200 reports

Purchase Reports From Reputable Market Research Publishers

Lung Cancer Drug Pipeline Update 2014

Lung Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R&D ...

  • Industries : Drug and Medication
Ovarian Cancer Drug Pipeline Update 2014

Ovarian Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for existing ...

  • Industries : Drug and Medication
Pancreatic Cancer Drug Pipeline Update 2014

Pancreatic Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

There are today 277 companies plus partners developing 347 drugs targeting pancreatic cancer in development. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last ...

  • Industries : Drug and Medication
Prostate Cancer Drug Pipeline Update 2014

Prostate Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various ...

  • Industries : Drug and Medication
Renal Cancer Drug Pipeline Update 2014

Renal Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being ...

  • Industries : Drug and Medication
Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014

Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

There are today 169 companies plus partners developing 227 calcium signaling pathway targeting drugs in 871 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated ...

  • Industries : Drug and Medication
Cell Cycle Targeting in Cancer Drug Pipeline Update 2014

Cell Cycle Targeting in Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

There are today 143 companies plus partners developing 165 targeting the cell cycle drugs in 581 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ...

  • Industries : Drug and Medication
Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2014

Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the ...

  • Industries : Drug and Medication
Targeting Natural Killer Cell Mediated Cytotoxicity in Cancer Drug Pipeline Update 2014

Targeting Natural Killer Cell Mediated Cytotoxicity in Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

Natural killer (NK) cells are lymphocytes of the innate immune system that are involved in early defenses against both allogeneic (nonself) cells and autologous cells undergoing various forms of stress, ...

  • Industries : Drug and Medication
Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update 2014

Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

There are today 184 companies plus partners developing 323 targeting actin cytoskeleton modulators drugs in 1264 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated ...

  • Industries : Drug and Medication
Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014

Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified ...

  • Industries : Drug and Medication
VEGF Signaling Pathway in Cancer Drug Pipeline Update 2014

VEGF Signaling Pathway in Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

There is now much evidence that VEGFR-2 is the major mediator of VEGF-driven responses in endothelial cells and it is considered to be a crucial signal transducer in both physiologic and pathologic angiogenesis. ...

  • Industries : Drug and Medication
Targeting Metabolic Pathways in Cancer Drug Pipeline Update 2014

Targeting Metabolic Pathways in Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

There are today 162 companies plus partners developing 180 metabolic pathways targeting drugs in 485 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated numbe ...

  • Industries : Drug and Medication
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014

ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, ...

  • Industries : Drug and Medication
Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2014

Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

Inflammatory immune response requires the recruitment of leukocytes to the site of inflammation upon foreign insult. Chemokines are small chemoattractant peptides that provide directional cues for the ...

  • Industries : Drug and Medication
Transcriptional Misregulation in Cancer Drug Pipeline Update 2014

Transcriptional Misregulation in Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

There are today 223 companies plus partners developing 300 transcriptional misregulation targeting drugs in 1227 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated ...

  • Industries : Drug and Medication
HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2014

HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

Cancer cells are characterized by rapid proliferation and require adaptive metabolic responses to allow continued biosynthesis and cell growth in the setting of decreased oxygen (O(2)) and nutrient availability. ...

  • Industries : Drug and Medication
Orphan Drugs in Oncology Drug Pipeline Update 2014

Orphan Drugs in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

This is a worldwide report on cancer drugs which have now or in the past received orphan drug status. This product will give you unique access not only to those cancer indications in which drugs are being ...

  • Industries : Drug and Medication
Conjugated Drugs in Oncology Drug Pipeline Update 2014

Conjugated Drugs in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

Among conjugated drugs in oncology, antibody-drug conjugates (ADCs) are by far getting the most attention as a new drug class. Owing to improved technology and appropriate targeting, the clinical application ...

  • Industries : Drug and Medication
Mitochondrial Drugs in Oncology Drug Pipeline Update 2014

Mitochondrial Drugs in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

Focusing on mitochondria has recently become an intriguing target for cancer therapy. It is well known that mitochondrial activity in tumor cells is suppressed and exploiting the differences in mitochondrial ...

  • Industries : Drug and Medication
MicroRNAs in Cancer Drug Pipeline Update 2014

MicroRNAs in Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

The hot entry of microRNA (miRNA) targeting drugs in oncology may come to revolutionize how we in the near future can launch a highly tumor-specific, multi-targeted attack with minimal toxicities eithe ...

  • Industries : Drug and Medication
EU: Heterocyclic Compounds - Market Report. Analysis and Forecast to 2020

EU: Heterocyclic Compounds - Market Report. Analysis and Forecast to 2020

  • $ 2 161
  • Industry report
  • December 2014
  • by IndexBox Marketing

The report provides an in-depth analysis of the EU Market of Heterocyclic Compounds. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics ...

  • Industries : Drug and Medication
  • Countries : Europe, Czech Republic, United Kingdom, Netherlands, Luxembourg, Lithuania, World, Sweden, Spain, Slovenia, Slovakia (slovak Republic), Romania, Portugal, Poland, Malta, Latvia, Italy, Ireland, Hungary, Greece, France, Germany, Finland, Estonia, Denmark, Cyprus, Croatia, Bulgaria, Belgium, Austria
EU: Lactams From Heterocyclic Compounds - Market Report. Analysis and Forecast to 2020

EU: Lactams From Heterocyclic Compounds - Market Report. Analysis and Forecast to 2020

  • $ 2 161
  • Industry report
  • December 2014
  • by IndexBox Marketing

The report provides an in-depth analysis of the EU Market of Lactams From Heterocyclic Compounds. It presents the latest data of the market size and volume, domestic production, exports and imports, price ...

  • Industries : Drug and Medication
  • Countries : Europe, Czech Republic, United Kingdom, Netherlands, Luxembourg, Lithuania, World, Sweden, Spain, Slovenia, Slovakia (slovak Republic), Romania, Portugal, Poland, Malta, Latvia, Italy, Ireland, Hungary, Greece, France, Germany, Finland, Estonia, Denmark, Cyprus, Croatia, Bulgaria, Belgium, Austria
EU: Hormones, Prostaglandins, Thromboxanes And Leukotrienes - Market Report. Analysis and Forecast to 2020

EU: Hormones, Prostaglandins, Thromboxanes And Leukotrienes - Market Report. Analysis and Forecast to 2020

  • $ 2 161
  • Industry report
  • December 2014
  • by IndexBox Marketing

The report provides an in-depth analysis of the EU Market of Hormones, Prostaglandins, Thromboxanes And Leukotrienes. It presents the latest data of the market size and volume, domestic production, exports ...

  • Industries : Drug and Medication
  • Countries : Europe, Czech Republic, United Kingdom, Netherlands, Luxembourg, Lithuania, World, Sweden, Spain, Slovenia, Slovakia (slovak Republic), Romania, Portugal, Poland, Malta, Latvia, Italy, Ireland, Hungary, Greece, France, Germany, Finland, Estonia, Denmark, Cyprus, Croatia, Bulgaria, Belgium, Austria
EU: Antibiotics - Market Report. Analysis and Forecast to 2020

EU: Antibiotics - Market Report. Analysis and Forecast to 2020

  • $ 2 161
  • Industry report
  • December 2014
  • by IndexBox Marketing

The report provides an in-depth analysis of the EU Market of Antibiotics. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnove ...

  • Industries : Drug and Medication
  • Countries : Europe, Czech Republic, United Kingdom, Netherlands, Luxembourg, Lithuania, World, Sweden, Spain, Slovenia, Slovakia (slovak Republic), Romania, Portugal, Poland, Malta, Latvia, Italy, Ireland, Hungary, Greece, France, Germany, Finland, Estonia, Denmark, Cyprus, Croatia, Bulgaria, Belgium, Austria
EU: Vaccines For Human Medicine - Market Report. Analysis and Forecast to 2020

EU: Vaccines For Human Medicine - Market Report. Analysis and Forecast to 2020

  • $ 2 161
  • Industry report
  • December 2014
  • by IndexBox Marketing

The report provides an in-depth analysis of the EU Market of Vaccines For Human Medicine. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics ...

  • Industries : Drug and Medication
  • Countries : Europe, Czech Republic, United Kingdom, Netherlands, Luxembourg, Lithuania, World, Sweden, Spain, Slovenia, Slovakia (slovak Republic), Romania, Portugal, Poland, Malta, Latvia, Italy, Ireland, Hungary, Greece, France, Germany, Finland, Estonia, Denmark, Cyprus, Croatia, Bulgaria, Belgium, Austria
Russia: Heterocyclic Compounds - Market Report. Analysis and Forecast to 2020

Russia: Heterocyclic Compounds - Market Report. Analysis and Forecast to 2020

  • $ 2 161
  • Industry report
  • December 2014
  • by IndexBox Marketing

The report provides an in-depth analysis of the Russian Market of Heterocyclic Compounds. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics ...

  • Industries : Drug and Medication
  • Countries : Russian Federation
Russia: Lactams From Heterocyclic Compounds - Market Report. Analysis and Forecast to 2020

Russia: Lactams From Heterocyclic Compounds - Market Report. Analysis and Forecast to 2020

  • $ 2 161
  • Industry report
  • December 2014
  • by IndexBox Marketing

The report provides an in-depth analysis of the Russian Market of Lactams From Heterocyclic Compounds. It presents the latest data of the market size and volume, domestic production, exports and imports, ...

  • Industries : Drug and Medication
  • Countries : Russian Federation
Russia: Hormones, Prostaglandins, Thromboxanes And Leukotrienes - Market Report. Analysis and Forecast to 2020

Russia: Hormones, Prostaglandins, Thromboxanes And Leukotrienes - Market Report. Analysis and Forecast to 2020

  • $ 2 161
  • Industry report
  • December 2014
  • by IndexBox Marketing

The report provides an in-depth analysis of the Russian Market of Hormones, Prostaglandins, Thromboxanes And Leukotrienes. It presents the latest data of the market size and volume, domestic production, ...

  • Industries : Drug and Medication
  • Countries : Russian Federation
Russia: Antibiotics - Market Report. Analysis and Forecast to 2020

Russia: Antibiotics - Market Report. Analysis and Forecast to 2020

  • $ 2 161
  • Industry report
  • December 2014
  • by IndexBox Marketing

The report provides an in-depth analysis of the Russian Market of Antibiotics. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnove ...

  • Industries : Drug and Medication
  • Countries : Russian Federation
About 12 000 reports

Download Unlimited Documents from Trusted Public Sources

Drug Industry - Forecast

  • December 2014
    73 pages
  • Drug  

  • Europe  

    United States  

    India  

View report >

Drug Industry In Canada

December 2014

Drug Industry In The Us

December 2014

62 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Johnson and Johnson

United States

Pfizer Inc.

United States

Novartis Inc.

Switzerland

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.